Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney diseaseWirkungen von Paricalcitol auf kardiovaskuläre Ergebnisse und Nierenfunktion bei Patienten mit chronischer Nierenerkrankung

X. Hu,J. Shang,W. Yuan,S. Zhang,Y. Jiang,B. Zhao,Y. Duan,J. Xiao,Z. Zhao
DOI: https://doi.org/10.1007/s00059-017-4605-y
2018-01-01
Herz
Abstract:Paricalcitol, a selective activator of the vitamin D receptor (VDR), influences calcium and phosphorus homeostasis and bone metabolism. Whether paricalcitol reduces cardiovascular risk and protects renal function remains unclear. To systematically evaluate this in patients with chronic kidney disease (CKD), we conducted a meta-analysis of published randomized controlled trials (RCTs).
What problem does this paper attempt to address?